Salubris Pharmaceuticals

Salubris Pharmaceuticals, also known as Shenzhen Salubris Pharmaceuticals and 信立泰 in Chinese, is a Chinese pharmaceutical company headquartered in Shenzhen. The company was founded in November 1998 and operates in the pharmaceutical sector, with activities associated with cardiovascular medicine, oncology, and other therapeutic areas. Its business is centered on the development, manufacture, and commercialization of medicines for the Chinese market. Salubris is listed on the Shenzhen Stock Exchange under ticker 002294. Public reference material identifies Ye Chenghai as the company’s head. The available reference information does not provide a sufficiently detailed account of the company’s individual drug brands, research pipeline, international subsidiaries, founding ownership structure, or current management roster, so those areas are not expanded beyond what can be supported. Salubris is best understood as a China-focused pharmaceutical corporate brand rather than a consumer healthcare label. Its positioning reflects the broader Chinese prescription-drug industry, where therapeutic specialization, regulatory approvals, manufacturing capability, hospital access, and reimbursement conditions are important determinants of commercial performance. The company’s stated or reported therapeutic emphasis on cardiovascular and oncology treatment places it in areas with substantial clinical need and long-term demand, while its broader pharmaceutical activities indicate that it is not limited to a single drug category. No current website, detailed operating-market list beyond China, or verified current financial metrics were provided in the source material for this entry.

Salubris Pharmaceuticals is a pharmaceutical company based in Shenzhen, China. It was established in November 1998 and developed as a Chinese drug-industry business serving domestic therapeutic markets. The available reference identifies its activities with cardiovascular medicine, oncology, and other pharmaceutical areas, but does not provide a complete chronology of product approvals, acquisitions, research partnerships, or overseas expansion. Accordingly, the company’s documented history can be summarized at a high level rather than reconstructed as a detailed corporate timeline. The company’s development reflects the growth of China’s modern pharmaceutical sector, in which domestic manufacturers have sought to build capabilities in drug research, production, regulatory compliance, and commercialization. Salubris has been associated with prescription medicines rather than with a consumer-facing healthcare portfolio. Its reported therapeutic interests in cardiovascular and oncology medicine place it in fields requiring specialized clinical development and regulatory authorization. These areas also tend to involve sustained demand because of the prevalence of cardiovascular disease and the continuing need for cancer treatment. Salubris became a publicly traded company on the Shenzhen Stock Exchange under ticker 002294. The listing gave the company access to public capital markets and established it as a listed Chinese pharmaceutical enterprise. The reference material identifies Ye Chenghai as the company’s head. It does not, however, establish whether he was the founder, provide a complete list of former or current executives, or specify the company’s ownership structure. By the period covered by the available reference material, Salubris remained headquartered in Shenzhen and primarily associated with the Chinese market. A 2019 reference describes the company as having 3,121 employees and annual sales of US$553 million, but those figures are historical and are not repeated here as current financial information. The same material mentions a market capitalization figure for 2019; because market capitalization changes over time and no current valuation source is supplied, it is omitted from the profile. Detailed information about individual brands, major products, clinical programs, international operations, campaigns, controversies, and strategic transactions is not available in the supplied sources.

• 1998

  Company founded

  [1]Salubris Pharmaceuticalsen.wikipedia.org

  Salubris Pharmaceuticals was founded in November 1998 in China.

• Shenzhen Stock Exchange listing

  [1]Salubris Pharmaceuticalsen.wikipedia.org

  Salubris Pharmaceuticals became listed on the Shenzhen Stock Exchange under ticker 002294; the supplied reference does not state the listing date.

A China-focused pharmaceutical manufacturer and developer serving prescription-drug and therapeutic-care markets, with reported emphasis on cardiovascular and oncology treatments.

• Cardiovascular pharmaceuticals

  Cardiovascular medicines

  A reported core therapeutic area for Salubris. The supplied reference identifies cardiovascular medicine as part of the company’s focus but does not name specific active ingredients, branded products, indications, or product-generation history.

• Oncology pharmaceuticals

  Oncology medicines

  Salubris is also associated with oncology pharmaceuticals. Available material does not identify particular oncology products, development stages, approvals, or commercial launch dates, so this entry describes the therapeutic area rather than a named product line.

• Prescription pharmaceuticals

  Other therapeutic-area medicines

  Beyond cardiovascular and oncology medicine, Salubris is described as operating across other therapeutic areas. The supplied sources do not provide a reliable product catalogue or enough detail to identify additional named lines.

1. 1Salubris Pharmaceuticalsen.wikipedia.org